Thomas M. Aaberg, Jr., MD, PhD
Retina Specialists of Michigan / CMO - Neurotech
Caroline Baumal, MD
Apellis / New England Eye Center, Tufts Medical Center
Robert B. Bhisitkul, MD, PhD
University of California San Francisco School of Medicine
Pierre Billardon
DORC International B.V.
David Boyer, MD
Retina Vitreous Associates Medical Group
Paul Bresge
Ray Therapeutics
Greg Butz
Bank of America Merrill Lynch
Thomas A. Ciulla, MD, MBA, FASRS
Viridian Therapeutics / Indiana University School of Medicine / Midwest Eye Institute
Eugene de Juan, MD
UCSF Department of Ophthalmology
Pravin U. Dugel, MD
Ocular Therapeutix
David A. Eichenbaum, MD
Retina Vitreous Associates of Florida
David Esposito
ONL Therapeutics
Claire Gelfman, PhD
Foundation Fighting Blindness
Shamika Gune, MD
Genentech
Paul Hallen
Alcon
Erin Henry, PhD
NGM Biopharmaceuticals
Nancy Holekamp, MD
Pepose Vision Institute
J. Jill Hopkins, MD
Novartis
Jean-Pierre Hubschman, MD
Stein Eye Institute at UCLA
Mark S. Humayun, MD, PhD
University of Southern California Roski Eye Institute
Peter Kaiser, MD
Cole Eye Institute
Jerry Lee, MBA
Goldman Sachs
James C. Murray
ExSight Ventures
Aaron Nagiel, MD, PhD
Keck School of Medicine of USC
John S. Pollack, MD
jCyte
Firas Rahhal, MD
ExSight Ventures & Retina Vitreous Associates Medical Group
Robert Rothman, MD
InFocus Capital Partners / OCLI/Glaucoma Consultants of Long Island
Russell Trenary
Outlook Therapeutics
Glenn C. Yiu, MD, PhD
UC Davis Health Department of Ophthalmology & Vision Science
